Skip to main content
Acticor Biotech logo

Acticor Biotech — Investor Relations & Filings

Ticker · ALACT ISIN · FR0012519668 LEI · 969500K433EK1G89EV95 PA Manufacturing
Open in API
Filings indexed 200 across all filing types
Latest filing 2023-10-26 Interim / Quarterly Rep…
Country FR France
Listing PA ALACT

About Acticor Biotech

https://www.acticor-biotech.com

Acticor Biotech is a clinical-stage biopharmaceutical company that originated as a spin-off from the French National Institute of Health and Medical Research (INSERM). The company is dedicated to developing innovative treatments for thrombotic diseases, with a primary focus on the acute phase of ischemic stroke. Its lead drug candidate, glenzocimab, is a humanized monoclonal antibody fragment designed to target platelet glycoprotein VI (GPVI), a key receptor involved in thrombosis. The therapeutic approach aims to provide an effective anti-thrombotic effect to safely manage stroke patients without increasing the risk of bleeding, a significant complication associated with existing treatments.

Recent filings

Filing Released Lang Actions
Rapports financiers et d'audit semestriels/examens réduits / Rapport financier semestriel
Interim / Quarterly Report Classification · 100% confidence The document is explicitly titled 'RAPPORT FINANCIER SEMESTRIEL AU 30 JUIN 2023' (Half-Year Financial Report as of June 30, 2023). It contains comprehensive financial statements (Balance Sheet, Income Statement, Cash Flow Statement), notes to the financial statements, and a management activity report. It is a formal interim financial report, not an announcement or a summary. H2 2023
2023-10-26 French
Half yearly financial reports and audit reports/limited reviews / Half yearly financial report
Interim / Quarterly Report Classification · 100% confidence The document is explicitly titled 'HALF-YEAR FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2023'. It contains comprehensive financial statements (Statement of Financial Position, Income Statement, Cash Flows, etc.), notes to the financial statements, an activity report, and a responsibility statement from the CEO. It is a full interim report, not an announcement or a summary, and meets the criteria for an Interim/Quarterly Report. H2 2023
2023-10-26 English
Inside Information / News release on accounts, results
Interim / Quarterly Report Classification · 95% confidence The document is a press release from Acticor Biotech announcing its half-year results for 2023. It contains key financial highlights, an income statement summary, and updates on clinical trials and governance. While it references the full financial report being available on the company website, the document itself provides substantive financial data (income statement, R&D costs, cash position) for the interim period (six months ending June 30, 2023). Therefore, it qualifies as an Interim/Quarterly Report (IR) rather than a mere announcement (RPA). H2 2023
2023-10-26 English
Inside Information / Other news releases
Regulatory Filings Classification · 90% confidence The document is a press release dated October 12, 2023, announcing the participation of Acticor Biotech in the 15th World Stroke Congress (WSC 2023) and detailing the presentations made regarding their drug glenzocimab. It summarizes clinical data presentations (Oral Presentation, e-Poster) from a conference. This type of announcement, which communicates company activities, research findings, and participation in industry events, does not fit the definitions for formal regulatory filings like 10-K, IR, ER, or DEF 14A. It is a general corporate communication about research progress and industry engagement. Since there is no specific category for 'Conference Participation Announcement' or 'Research Update Press Release,' and it is not a formal financial report, the most appropriate fallback category is 'Regulatory Filings' (RNS), which serves as a general category for miscellaneous corporate announcements that do not fit elsewhere.
2023-10-12 English
Informations privilégiées / Autres communiqués
Investor Presentation Classification · 90% confidence The document is a press release dated October 12, 2023, announcing the participation of Acticor Biotech in the 15th World Stroke Congress (WSC 2023) and detailing the presentations made regarding their drug, glenzocimab. It summarizes clinical trial data (ACTIMIS, ACTISAVE) presented at a medical conference. This content is not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). It is an announcement about scientific/clinical data dissemination at an industry event. This type of communication, focusing on clinical trial updates and scientific presentations, is best categorized as an Investor Presentation (IP) or, more broadly, a general regulatory/corporate announcement. Given the focus on presenting scientific data and clinical progress to the market, 'Investor Presentation' (IP) is a strong fit, as these often accompany or summarize such scientific disclosures. However, since it is structured as a press release announcing participation and summarizing presentations, and does not contain the full presentation slides, it functions as a corporate update on R&D progress. If the options were broader, 'Research Update' would fit best. Among the provided codes, 'Investor Presentation' (IP) captures the essence of communicating clinical/scientific progress to investors, although it is technically a press release summarizing conference activity. Since it is a detailed summary of scientific findings presented at a conference, it aligns closely with the information typically found in an Investor Presentation, rather than a general Regulatory Filing (RNS).
2023-10-12 French
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social au 30 septembre 2023" (Monthly information relating to the total number of voting rights and shares comprising the share capital as of September 30, 2023). It explicitly references Article 223-16 of the AMF General Regulation and provides a table detailing the total number of shares and theoretical/real voting rights as of a specific date (30/09/2023). This type of regular disclosure concerning the total number of shares and voting rights is a specific regulatory requirement, often related to capital structure changes or general shareholder information. While it is a regulatory announcement, the specific content—the monthly count of shares and voting rights—is most closely aligned with notifications regarding capital structure or major shareholding changes, but the most precise fit among the provided codes for this specific recurring regulatory disclosure is often related to capital changes or major shareholding notifications. However, since it is a mandatory monthly disclosure of the total share count and voting rights, it is a fundamental piece of corporate governance/capital structure information. Given the options, it is not a Director's Dealing (DIRS), a Dividend Notice (DIV), or a Major Shareholding Notification (MRQ) which usually reports *changes* by specific entities crossing thresholds. It is a general capital structure update. The closest fit for a general, mandatory disclosure about the total number of shares and voting rights, which is a key component of capital structure reporting, is often grouped under Capital/Financing Update (CAP) or sometimes Regulatory Filings (RNS) if no better fit exists. Since it is a formal, recurring report on the total share count, it is a fundamental capital structure disclosure. Let's re-evaluate the options. It is not a 10-K, ER, or IR. It is not a proxy (PSI) or AGM material. It is a formal regulatory disclosure about the capital base. Option SHA (Share Issue/Capital Change) covers announcements regarding new share issues or capital changes. This document reports the *current state* of the capital base, which is a prerequisite for tracking changes. Option RNS (Regulatory Filings) is a fallback. Given the specific nature of reporting the total number of shares and voting rights monthly, this often falls under general capital structure reporting. In many jurisdictions, this specific filing is mandated under rules governing the total capital base. Since there isn't a perfect 'Total Share Count Disclosure' code, and it relates directly to the denominator of many financial metrics, it is a core capital structure update. I will classify it as SHA (Share Issue/Capital Change) as it pertains directly to the composition of the share capital, or RNS as a general regulatory filing. Given the highly specific nature of the content (voting rights and share count), and lacking a dedicated code, RNS is the safest fallback for a mandatory, non-financial results disclosure. However, if we interpret 'Capital Change' broadly to include the reporting of the current capital base, SHA might apply. Let's check the definitions again. SHA is for 'new share issues, stock splits, or other capital changes.' This is a report *on* the capital, not necessarily announcing a *change*. Therefore, RNS (General regulatory announcements and fallback) is the most appropriate classification for this mandatory monthly disclosure that doesn't fit the specific financial report or transaction codes.
2023-10-04 French

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.